A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT07751341 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG: SHR-9839(sc) for Injection
DRUG: SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.